Navigation Links
US Pharmacopeia announces revised heparin monographs and reference standards
Date:6/23/2008

Rockville, Md., June 23, 2008 The U.S. Pharmacopeial (USP) Convention announces that revised monographs for heparin sodium and heparin calcium in the United States Pharmacopeia (USP) are now available and official on the USP Web site. The revised monographs are accompanied by two new and two updated official USP Reference Standards. These public standards allow any partyand particularly the Food and Drug Administration (FDA) and manufacturersto test heparin sodium and calcium drug substances to assure their quality. All drug manufacturers who market heparin in the United States are required to meet these newly revised standards. The heparin monographs were updated in the interest of public health following the deaths of more than 200 people earlier this year. These deaths are suspected to have resulted from the adulteration of the blood thinner with over-sulfated chondroitin, which is derived from the chemical chondroitin and used in dietary supplements.

The two heparin monographs are posted on the USP Web site at http://www.usp.org/hottopics/heparin.html?hlc. These revisions mark the end of the first stage (Stage 1) of a multi-stage process to revise the monographs. The Stage 1 revision was intended to rapidly address the immediate public health crisis associated with the drug and help ensure an unadulterated supply of heparin by taking proposed methods from the FDA and improving their robustness. The second stage of revision (Stage 2) will seek out additional methods to test for over-sulfated chondroitin and other potential contaminants in heparin. USP co-sponsored a meeting June 19-20, 2008, in Strasbourg, France, with the European Directorate for the Quality of Medicines (the organization that elaborates the European Pharmacopoeia) and the United Kingdom's National Institute for Biological Standards and Control as part of a coordinated, worldwide effort to assure the quality and purity o
'/>"/>

Contact: Laura Provan
lnp@usp.org
301-816-8268
US Pharmacopeia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. U.S. Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination
2. U.S. Pharmacopeia Releases New Edition of the Food Chemicals Codex
3. US Pharmacopeia releases new edition of the Food Chemicals Codex
4. Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference
5. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
6. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
7. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
8. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
11. Pharmacopeia Announces Senior Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...J., Dec. 2 Cantel Medica... to discuss the Company,s results for its first qu...t 11:00 AM ET. Participating in the call will be ...esident; Craig A. Sheldon, Senior Vice President a...orporation. Minntech is a Cantel subsidiary. The f...
(Date:12/2/2008)... Ingenious Med (IM) welcomes new CE...der in inpatient practice,management solutions, w...are,software, revenue management, medical servic... nine-year CEO, Dr. Steven Liu, is confident Willi...opment in all sectors, as he steps into,the role....
(Date:12/2/2008)...moms who took it in first 3 months more likely to ...2 (HealthDay News) -- Infants whose mothers take f... an increased risk for respiratory illness, accord...ed to reduce the risk of birth defects, and many c... The researchers examined data on more than 32,000...
(Date:12/2/2008)... researchers at The University of Nottingham has i...cancer. , The research, published in the journal..., USA and funded by a 72,000 grant from the Britis...essor gene, LIMD1, is responsible for protecting t...y for possible new treatments and early screening ...
Breaking Medicine News(10 mins):Health News:Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:Gene which protects against lung cancer identified 2
...of developing pancreatic cancer increases by 90% w... // Pancreatic cancer risk was 70% higher in peopl...times a day when compared with those who added no ...r intake been already considered as a risk factor,...
...p of hospital services in east Lancashire by a cou...ers. // East Lancashire Hospitals NHS Trust has ... of Burnley's A&E department that will now not be ...the overview and scrutiny by the council’s committ...
...nother anti-polio drive Sunday even as new polio c... detected. During the drive, pulse polio drops wo...of up to five years of age, according to health of...case of polio was confirmed by the National Polio ...
...al Of American Medical Association announced that ... might not be completely bad. In fact a theory by ...as brought the association of heart attach and hig...r. Gheorghiade through his research found that dur...
Other Medicine News:Health News:Fury over Backing of Health Shake-up 2
(Date:11/25/2008)...nst expanding statin use broadly in wake of AHA-pr...25 JUPITER, a clinical trial sugge...sk of healthy patients with elevated CRP, should n...cording to a national poll directed at health prof...e online poll conducted by medical news site MedPa...
(Date:11/25/2008)... Poniard,Pharmaceutical...pany focused on,innovative oncology therapies, an... alternatives for its preclinical research program...urces on the clinical development of picoplatin,...tial commercialization of,picoplatin in the treat...
(Date:11/25/2008)...ial to Assess Survival of Patients Receiving Litx ... Hepatocellular Carcinoma , , BELLEVUE, Was...y, Inc. (LSO) today announced the completion of en...ht Infusion Therapy(TM) (Litx(TM)) as a treatment ...lso known as hepatoma or primary liver cancer. , ...
(Date:11/24/2008)...ov. 24 Takeda Pharmaceutical Compa... Global Research & Development Center, Inc., U...ommittee of the U.S. Food and Drug Administration ... for the treatment of hyperuricemia in patients wi...val, with one panel member abstaining. The vote fo...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Biophysical Society names 2009 award recipients 4751 1Biophysical Society names 2009 award recipients 4751 2Leaders in Pathology Meet in San Diego 3A Sept 25 28 2008 26107 1Leaders in Pathology Meet in San Diego 3A Sept 25 28 2008 26107 2HRSA Announces 2439 Million in Grants to Expand Improve Health Center Services 26105 1HRSA Announces 2439 Million in Grants to Expand Improve Health Center Services 26105 2Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year 7513 1Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year 7513 2
...pr 10, 2007 - Valeant,Pharmaceuticals Internationa...ase 2 data for retigabine, a first-in-class,neuron...ng,independent, scientific journal. The authors co...onstrated reduction in monthly,seizure rates in th... RESTORE2) are currently underway to further inves...
...es Insulin-Free, WASHINGTON, April 10, 2007 /PRNew...lt stem cell therapy, the Journal of the,American ...in which,14 of 15 Juvenile Diabetes patients demon...adult stem cell treatment. According,to U.S. Rep. ... in,that it,s the first attempt at using stem cell...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Newest Adult Stem Therapy Treats Diabetes 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump.
...ARE TVT is a minimally invasive, highly effective ...rinary incontinence. GYNECARE TVT is positioned cl...when needed, TVT provides tension-free support of ... takes approximately 20 to 30 minutes, with minima...
SUR-FIT® AutoLock® Urostomy Pouch with Accuseal® Tap
New Image Urostomy Pouch, Ultra-Clear
Medicine Products: